Sugi Predict

Sugi Predict / Compounds / SCHEMBL3829508

SCHEMBL3829508

SCHEMBL3829508

O=S(=O)(c1ccccc1)C(c1sc(NCc2cncc(F)c2)nc1Cl)c1c[nH]c2ncc(Cl)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 6/20 0.46
▸ CYP2C9 P11712 4/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ LMNA P02545 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NAMPT P43490 1/20 0.34
▸ CLK1 P49759 5/20 0.34
▸ DYRK1A Q13627 4/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ SNCA P37840 1/20 0.32
▸ LCK P06239 1/20 0.32
▸ PGR P06401 1/20 0.32
▸ CSF1R P07333 1/20 0.32
▸ CHRM2 P08172 1/20 0.32
▸ HTR1A P08908 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1268392 0.84 CYP2C9 (0.49) CYP3A4CYP2C9SMN1; SMN2PKMLMNA
SCHEMBL3822504 0.82 CYP3A4 (0.52) CYP3A4CYP2C9NAMPTCLK1DYRK1A
SCHEMBL1266831 0.79 JAK2 (0.41) CYP3A4SMN1; SMN2MAPTKMT2AJAK2
SCHEMBL3862095 0.75 LCK (0.37) CYP3A4JAK2LCKROCK1
SCHEMBL2381122 0.74 SMN1; SMN2 (0.41) CYP3A4CYP2C9SMN1; SMN2PKMLMNA
SCHEMBL1266436 0.73 CYP3A4 (0.65) CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6
SCHEMBL4512512 0.72 CYP2C9 (0.42) CYP3A4CYP2C9MAPTDYRK1ACYP2C19
SCHEMBL3829505 0.70 CYP2C9 (0.39) CYP3A4CYP2C9SMN1; SMN2PKMLMNA
SCHEMBL1266809 0.67 JAK2 (0.43) CYP3A4CYP2C9CYP2D6JAK2
SCHEMBL1885668 0.66 CYP3A4 (0.51) CYP3A4CYP2C9CLK1DYRK1ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2017-08-31 — — US disclosed
US-9487515-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2016-11-08 — — US disclosed
US-9169250-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2015-10-27 — — US disclosed
US-20150265586-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR DAIICHI SANKYO, INC. 2015-09-24 — — US disclosed
US-20140243365-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR DAIICHI SANKYO, INC. 2014-08-28 — — US disclosed
US-8722702-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2014-05-13 — — US disclosed
EP-2086972-B1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC (US) 2013-11-20 — — EP disclosed
US-20130178473-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. (US) 2013-07-11 — — US disclosed
US-8461169-B2 Compounds modulating c-fms and/or c-kit activity PLEXXIKON INC. (US) 2013-06-11 — — US disclosed
US-8404700-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2013-03-26 — — US disclosed
US-20120309756-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC 2012-12-06 — — US disclosed
EP-2086972-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2009-08-12 — — EP disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 — — US disclosed
WO-2008064255-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 — — WO disclosed
WO-2008063888-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 — — WO disclosed
WO-2008064265-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243365-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CYP3A4 3847/4885CYP2C9 4122/4885SMN1; SMN2 3816/4885
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CYP3A4 3847/4885CYP2C9 4122/4885SMN1; SMN2 3816/4885
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor KIT, FLT3, FLT1 CYP3A4 3847/4885CYP2C9 4122/4885SMN1; SMN2 3816/4885
US-20120309756-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CYP3A4 3847/4885CYP2C9 4122/4885SMN1; SMN2 3816/4885
US-20130178473-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CYP3A4 3847/4885CYP2C9 4122/4885SMN1; SMN2 3816/4885
US-20150265586-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CYP3A4 3847/4885CYP2C9 4122/4885SMN1; SMN2 3816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.